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Abstract
Background: Positron emission tomography (PET) images with amyloid tracers show normal uptake in healthy
white matter, which suggests that amyloid tracers are potentially useful for studying such white matter diseases as
multiple sclerosis (MS).
Methods: Twelve patients diagnosed with MS (5 with RRMS, 5 with SPMS, and 2 with PPMS) and 3 healthy controls
underwent studies with MRI and 18F-florbetaben-PET imaging. Images were preprocessed using Statistical Parametric
Mapping software. We analysed 18F-florbetaben uptake in demyelinating plaques (appearing as hyperintense lesions in
FLAIR sequences), in normal-appearing white matter, and in grey matter.
Results: Mean standardized uptake value relative to cerebellum was higher in normally appearing white matter
(NAWM) (1.51 ± 0.12) than in damaged white matter (DWM) (1.24 ± 0.12; P = .002). Mean percentage of change
between NAWM and DWM was −17.56 % ± 6.22 %. This percentage of change correlated negatively with EDSS scores
(r = −0.61, p < .05) and with age (r = −0.83, p < 0.01). Progressive forms of MS showed a more pronounced reduction of
the uptake in DWM in comparison to relapsing-remitting form.
Conclusions: Uptake of 18F-florbetaben in damaged white matter is lower than that occurring in normally-appearing
white matter. These findings indicate that amyloid tracers may be useful in studies of MS, although further research is
needed to evaluate the utility of amyloid-PET in monitoring MS progression.
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Background
Multiple sclerosis (MS) is an inflammatory neurodegen-
erative disease of the central nervous system in which
characteristic demyelinating lesions appear in the white
matter [1]. Magnetic resonance imaging (MRI) is the
most widely used, most sensitive, and most specific tech-
nique for identifying white and grey matter lesions. In
fact, this technique plays a crucial role that is specified
by current diagnostic criteria [2, 3].
Positron emission tomography (PET) is a functional
imaging technique in which radiotracers are used to
study numerous biological processes. PET findings are
an important biomarker in some neurological disorders
[4] such as dementia [5, 6]. Recently, there has been a
growing interest in exploring the potential applications
of PET in MS studies [7, 8]. In this regard, several
tracers are being studied, such as ligands of the 18kDA
translocator protein as a microglial activation marker
(ie. PK11195, PRB28), as well as 11C-acetate, ligands
of monoamine oxidase B and I2-imidazoline receptor
to study astrocyte metabolism and activation [9, 10].
In the past few years, researchers have developed sev-
eral PET radiotracers that permit in vivo studies of
amyloid-beta deposits. Important radiotracers include
11C-Pittsburgh compound B (11C-PiB) and 18F-labelled
PETamyloid tracers such as 18F-florbetaben, 18F-florbetapir,
and 18F-flutemetamol [11, 12]. Studies in healthy subjects
have demonstrated amyloid tracer uptake by white matter,
which suggests that the tracers may also be used in white
matter studies. A recent study employing 11C-PiB in ba-
boons and 2 patients with MS suggests that this tracer may
be used as a marker of myelin loss and repair in
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demyelinating diseases [13]. However, experience with
amyloid tracers in the study of white matter diseases is still
limited [14, 15].
Our purpose is to study 18F-florbetaben uptake in




Our study was approved by the hospital ethics com-
mittee and meets the standards established by the
Declaration of Helsinki. All patients signed informed
consent forms. Written informed consent for publica-
tion of their clinical details and/or clinical images was
obtained from the patients. We included 12 patients
diagnosed with MS according to the 2010 revision of
the McDonald criteria [2]: 5 patients had relapsing-
remitting MS (RRMS), 5 had secondary-progressive
MS (SPMS), and 2 had primary-progressive MS
(PPMS). Patients’ mean age was 47.3 years (range,
41–61); 9 were female (75 %), and mean time since
the onset was 13.2 years (range, 3.5–19). Mean Expanded
Disability Status Scale (EDSS) score was 4.9 (range,
3.5–6.5) (Table 1). Patients had not suffered any re-
lapse during the previous 6 months, and were not on
active treatment with corticosteroids or interferon. No
patient had gadolinium-enhancement on MRI brain
lesions. We also included 3 healthy subjects with 48,
50 and 52 years (1 male, 2 females). These subjects
were voluntary and did not have a family history of either
MS or Alzheimer’s disease. In all subjects, neuropsycho-
logical assessment was performed, in order to confirm
that cognitive deficits were related only to MS in the pa-
tient’s group, and to exclude cognitive impairment in the
healthy control group.
Image acquisition
All subjects underwent brain MRI and 18F-florbetaben-
PET studies.
MRI imaging was performed using a 1.5 T scanner
(Signa HDxt, GE Healthcare, Milwaukee, USA). The
protocol consisted of the following sequences:
1) T1-weighted 3D fast spoiled gradient-echo (FSPGR)
inversion recovery sequence (axial plane; repetition
time [TR], 12 ms; echo time [TE], 2.3 ms; inversion
time [TI], 400 ms; slice thickness, 3 mm; spacing,
0.0 mm; number of excitations [NEX], 1; matrix,
256 × 192; and field of view [FOV], 25 × 20 cm).
2) T2-weighted fluid-attenuated inversion recovery
(FLAIR) sequence (axial and sagittal plane; TR,
9102 ms; TE, 121 ms; TI, 2250 ms; slice thickness,
4 mm; spacing, 0.4 mm; NEX, 1; matrix, 256 × 192;
FOV, 24 cm).
3) T2-weighted double-echo fast spin-echo (FSE)
sequence (axial plane; TR, 2620 ms; TE 15/90 ms; echo
train length [ETL], 8; slice thickness, 3 mm; spacing,
0.0 mm; NEX, 2; matrix, 256 x 256; FOV, 22 cm).
Table 1 Demographic data and main variables for each patient














1 42 F RR 3.5 3.5 Azathioprine 24.13 1.14 1.36 173.00 −16.04
2 42 F RR 14 4.0 Fingolimod 51.83 1.21 1.27 131.80 −4.51
3 43 F RR 12 4.0 Fingolimod 10.01 1.45 1.67 193.11 −12.98
4 44 F RR 15 4.0 Natalizumab 58.30 1.37 1.57 149.43 −12.61
5 47 F RR 12 3.5 Fingolimod 52.06 1.20 1.46 163.85 −17.60
6 41 M SP 19 5.0 Fingolimod 47.49 1.41 1.61 155.32 −12.41
7 46 M SP 17 5.0 Glatiramer acetate 19.23 1.25 1.60 186.48 −22.10
8 47 F SP 16 5.0 Fingolimod 34.06 1.18 1.57 182.44 −24.47
9 48 M SP 14 6.0 Teriflunamide 40.0 1.28 1.54 170.71 −17.11
10 50 M SP 11 6.5 Azathioprine 45.60 1.09 1.45 178.60 −24.62
11 50 F PP 14 6.0 Glatiramer acetate 8.58 1.31 1.70 189.53 −22.63
12 61 F PP 11 6.5 None 16.69 1.07 1.40 157.32 −23.71
C-1 48 F - - - - - 185.20 **
C-2 50 M - - - - - 185.60 **
C-3 52 F - - - - - 185.00 **
C Healthy control, DWM damaged white matter, EDSS expanded disability status scale, F female, M male, NAWM normally-appearing white matter;
PP primary-progressive, RR relapsing-remitting, SP secondary-progressive, SUVRc standardized uptake value relative to cerebellum, WM white matter
aTime since onset is given in years from the first exacerbation or symptom
aIn healthy controls, uptake change was estimated between total white matter and the mean of the uptake in the ROIs of DWM developed for the MS patients
Matías-Guiu et al. BMC Neurology  (2015) 15:243 Page 2 of 7
4) T1-weighted post-contrast FSE sequence (TR, 640;
TE, 11.8; ETL, 2; slice thickness, 3 mm; spacing,
0.0 mm; NEX, 2; matrix, 256 × 192; FOV, 22 cm).
Gadoteric acid (Dotarem, Guerbet) was administered
at a standard dose of 0.1 mmol/kg for each MRI
study; T1-weighted post-contrast images were ac-
quired 5 minutes after contrast injection.
PET tests were performed using a Siemens Biograph™
TruePoint™ PET-CT platform with lutetium oxyorthosili-
cate crystals and 6-slice CT integrated with a latest-
generation PET scanner. 18F-florbetaben was administered
intravenously at a mean dose of 300 MBq. Static images
were taken 90 minutes after injection of the tracer. A sec-
ond set of images was acquired at 120 minutes in 5 of 12
patients. Acquisition time was 15 minutes. The recon-
struction was performed using the true X method with 2
iterations and 21 subsets. We used a 30 cm field of view
and a Gaussian filter with full width at half maximum of
4 mm. All results are given for acquisition at 90 minutes,
unless otherwise specified.
Image preprocessing and analysis
Images were preprocessed using Statistical Parametric
Mapping software version 8 (SPM8) (The Wellcome
Trust Centre for Neuroimaging, Institute of Neurology,
University College of London) [16]. Each patient’s
T1-weighted MRI image was co-registered with the
PET image using the normalized mutual information
technique, with the T1-weighted image as the refer-
ence image. The T1-weighted MRI image was warped to
Montreal Neurological Institute (MNI) space using the T1
template provided by SPM8 to define the warp parame-
ters. The same warp parameters were subsequently ap-
plied to normalize co-registered PET images to MNI
space. Likewise, T1-weighted images were segmented into
grey matter, white matter, and cerebrospinal fluid prob-
ability maps. Lesions in T1-weighed images were previ-
ously filled using the lesion filling tool provided by Lesion
Segmentation Tool (see below) to ensure an appropriate
preprocessing of images [17].
We performed a region of interest (ROI) analysis using
MarsBaR software and the Automated Anatomical La-
beling (AAL) atlas [18]. The ROI corresponding to each
patient’s total white matter (TWM) was generated based
on the white matter probability map. The AAL atlas was
used to delimit white matter in the frontal, limbic, par-
ietal, temporal, occipital, and sublobar regions in both
hemispheres. We used the intersection of regions in the
atlas with regions obtained from each patient to define
ROIs using the ImCalc function in SPM8.
The Lesion Segmentation Tool, developed by Schmidt
et al. [19], was used to detect white matter lesions. This
tool is based on an algorithm developed and validated
for automatic segmentation of T2 hyperintense white
matter lesions in MS. Segmentation is performed using a
T2-weighted FLAIR imaging sequence and a 3D gradient
echo T1-weighted sequence. A threshold K value of 0.3
was used [19]. ROIs of the white matter lesions were
based on probability maps. We made sure that each of
the ROIs obtained from the probability maps corre-
sponded to a real lesion and eliminated any unnecessary
ROIs. The adequate coregistration, normalization and
agreement between lesion probability maps and lesions
visually observed in MRI were checked by two of the
researchers (JAM-G, MNC-M). Following this step, a
single ROI for the damaged white matter (DWM)
(i.e. T2-weighted FLAIR imaging lesions) was cre-
ated. The ROI representing normal-appearing white
matter (NAWM) was calculated by subtracting the
DWM ROI from the TWM ROI (Fig. 1). Moreover, lesion
probability maps were used to fill the T1-weighted images
of each patient.
In healthy controls, imaging preprocessing was con-
ducted in the same manner. TWM was estimated by the
same procedure described above. In addition, the DWM
ROIs developed in MS patients was applied to the
healthy control, so that tracer uptake in the white matter
located in the regions frequently damaged in MS could
be evaluated.
Grey matter was evaluated using the following regions
from the AAL atlas: anterior cingulate, posterior cingu-
late, middle frontal gyrus (orbital part), superior parietal
gyrus, precuneus, superior temporal gyrus and superior
occipital gyrus [18]. We used cerebellum and NAWM as
the reference regions; results are presented as standard-
ized uptake values (SUVRc relative to the cerebellum;
SUVRwm relative to normally-appearing white matter).
Whole cerebellum was used as a reference region after
we checked that this region was not significantly im-
paired in the patients included in the study. In cases
with any cerebellar lesion, this was masked and excluded
from the analysis.
Manual ROI delineation
In addition to the semi-automatic analysis described
above, manual ROIs were generated by two raters (JAM-G,
MNC-M) in a Siemens Leonardo workstation. Four white
matters lesions (two periventricular and two juxtacortical)
were delineated for each patient in T2-weighted FLAIR im-
aging sequence; and two ROIs in the normal appearing
white matter. ROIs were used to calculate the SUV in the
coregistered PET.
Statistical analysis
Results are shown as means ± SD. We calculated the
percentage of change between NAWM and DWM as
follows: DWM uptake minus NAWM uptake, divided by
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NAWM uptake and multiplied by 100. The Mann–
Whitney U test was used to compare means between
two groups. The Wilcoxon test for paired samples was
used to compare the same patient’s uptake in different
regions (NAWM vs DWM, NAWM vs grey matter).
Correlations were calculated using the Spearman correl-
ation coefficient.
Results
Mean SUV relative to the cerebellum (SUVRc) was
higher in the NAWM (1.51 ± 0.12) than in the DWM
(1.24 ± 0.12; P = .002). Mean percentage of change be-
tween NAWM and DWM was −17.56 % ± 6.2 %. Table 1
shows the SUVRc for each of the patients. The lower
uptake in the white matter lesions was also observed in
the manual delineated ROIs (Table 2), in which mean
SUV in white matter lesions was 1.25 ± 0.21 and in nor-
mal appearing white matter was 1.76 ± 0.28 (P = .002).
The RR group had a lower percentage of change be-
tween NAWM and DWM (−12.74 ± 5.05 vs. -21.00 ± 4.5,
P = .04, respectively) and a lower EDSS score (3.80 ± 2.73
vs. 5.71 ± 0.69, P < .01) in comparison to the progressive
forms of MS. However, no significant differences were
obtained between both groups regarding age (43.60 ± 2.0
vs. 49.00 ± 6.11, P = .07) and total lesion volume in T2-
weighted MRI (39.47 ± 20.85 vs. 30.25 ± 15.37, P = .26).
In comparison to healthy controls, SUVRc in NAWM
was lower in MS than in the total white matter in
healthy controls (1.51 ± 0.12 vs. 1.74 ± 0.07, P = .01). This
finding was also observed with manually delineated ROIs
(SUV 1.76 ± 0.28 in MS vs. 2.36 ± 0.07 in healthy con-
trols, P = .009).
Mean SUVRc in MS patients for grey matter regions
was 0.93 ± 0.12 in the middle frontal gyrus (orbital part),
Fig. 1 NAWM and DWM segmentation a T1-weighted sequence; b FLAIR sequence; c NAWM (red) and white matter lesion (blue) segmentation
on a T1 template
Table 2 Standardized uptake value in ROIs manually delineated
Patients PV-1 PV-2 JC-1 JC-2 NAWM NAWM
1 1.28 0.86 1.07 0.96 1.58 1.56
2 0.83 0.93 0.93 0.94 1.41 1.27
3 1.68 1.52 1.51 1.35 2.09 2.10
4 1.38 1.40 0.78 1.61 1.61 1.86
5 1.47 1.50 1.57 2.02 2.12 2.28
6 1.27 1.04 1.66 1.75 2.07 2.27
7 0.90 1.54 1.57 1.61 1.77 1.78
8 1.30 1.47 0.82 1.17 1.76 2.13
9 1.11 1.12 0.91 1.01 1.42 1.49
10 1.20 0.97 1.32 0.90 1.70 1.57
11 1.29 1.52 0.96 1.10 1.78 1.69
12 1.12 1.23 1.28 1.31 1.52 1.60
Control 1 - - - - 2.35 2.25
Control 2 - - - - 2.30 2.39
Control 3 - - - - 2.37 2.51
PV periventricular lesion, JC juxtacortical lesion, NAWM normal appearing
white matter
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1.18 ± 0.11 in the anterior cingulate, 1.26 ± 0.12 in the
posterior cingulate, 1.17 ± 0.05 in the precuneus, 0.98
± 0.10 in the superior parietal gyrus, and 0.96 ± 0.08
in the superior temporal gyrus. Using white matter as
the reference region, SUVRwm was 0.61 ± 0.09 in the
middle frontal gyrus (orbital part), 0.78 ± 0.04 in the
anterior cingulate, 0.83 ± 0.05 in the posterior cingu-
late, 0.77 ± 0.06 in the precuneus, 0.64 ± 0.07 in the
superior parietal gyrus, and 0.63 ± 0.04 in the superior
temporal gyrus. The above demonstrates a lower up-
take by the grey matter than by the white matter
(results for each patient are shown in Additional file 1:
Table S1).
The percentage of change between NAWM and
DWM was negatively correlated with EDSS (r = −0.61,
P < .05) and age (r = −0.83, P < .001). No significant
correlations were found with the years of evolution of
the disease (r = 0.25, P > .05) and total lesion volume
on T2-weighted MRI (r = −0.36, P > .05). We esti-
mated a linear regression model to calculate the semi-
partial correlations (sr) between the percentage of change
and the variables age (sr = −0.339), MS form (sr =
−0.455), years of duration of the illness (sr = 0.262),
total lesion volume (sr = 0.038) and EDSS (sr = 0.264).
However, all semi-partial correlations were not were
not statistically significant (P > .05), with a trend in
the MS form (P = .063).
We also assessed potential differences in region dis-
crimination for images taken at a later point in time
(120 minutes after tracer injection) in 5 patients. In
this subgroup, SUVRc was 1.40 ± 0.10 for NAWM
and 1.15 ± 0.08 for DWM in the first series of images
at 90 minutes (P = 0.043); in the second series of im-
ages, mean SUVRc was 1.41 ± 0.13 for NAWM and
1.20 ± 0.07 for DWM (P = 0.043). The percentage of
change between DWM and NAWM was −17.19 ± 8.05 %
and −14.34 % ± 5.88 %, respectively. Correlation between
the percentage of change and EDSS was the same at 90
and 120 minutes (r = −0.87, P > .05). The mean area under
the curve for discrimination between the evaluated grey
matter regions and NAWM was 0.84 for the first acquisi-
tion and 0.86 for the second.
Discussion
Our study shows that 18F-florbetaben uptake in white
matter lesions in patients with MS is lower than in
NAWM. This finding was observed in all patients in the
study and was true of total DWM and of each of the in-
dividual lesions (Fig. 2). To the best of our knowledge,
this is the first study using 18F-labelled amyloid tracers
to investigate MS. Our findings are similar to those
reported by Stankoff et al. in a study of 2 patients with
MS who were analysed with PiB-PET. These authors
observed lower uptake in white matter lesions in
T1-weighted images [13].
Uptake of tracer in demyelinating lesions was 17.56 %
lower than in NAWM. This percentage is similar to that
reported in a previous study with PiB-PET [20] (Table 3).
Furthermore, patients with progressive forms of MS and
those with higher EDSS score displayed a more marked
reduction in uptake in DWM. In line with the previous
hypothesis that amyloid tracer fixation may be a marker
of demyelination/remyelination, the more marked re-
duction in uptake observed in PP and SP MS may be
associated with the reduced remyelination present in
progressive forms of the disease [21]. In the same
way, uptake reduction in DWM correlated with age.
This might also be explained by the decrease of
remyelination capacity with increasing age [22]. These
findings support the notion that amyloid tracers, and
Fig. 2 Co-registered MRI and 18F-florbetaben-PET images. a T1-weighted MRI. b Co-registered MRI and 18F-florbetaben-PET image. Arrows show
lesions and areas of low uptake detected using PET
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18F-florbetaben in particular, serve as markers of the
extent of white matter demyelination. This suggests
that amyloid tracers may indicate the state of myelin
in the central nervous system since they experience
non-specific uptake by white matter [13]. In this regard,
several studies have also observed lower PiB uptake in eld-
erly patients with white matter lesions [23, 24]. Although
semi-partial correlations were not statistically significant,
this might be explained by the small sample size that
limits the use of the regression analysis.
Another interesting result is the observation of a lower
uptake in NAWM in MS patients in comparison to
healthy subjects. The concept of normal-appearing white
matter is a matter of debate. MRI techniques, such as
diffusion tension imaging, PET studies with radioligands
of activated microglia, and pathological studies have
demonstrated abnormalities in NAWM [25, 26]. The
finding of a reduced 18 F-florbetaben uptake in NAWM
might support the role of amyloid ligands in the assess-
ment of the integrity of white matter. However, further
studies specifically designed to address this issue are ne-
cessary to be able to draw definitive conclusions.
Regarding image acquisition time, uptake differences
between DWM and NAWM at 120 minutes after tracer
injection were slightly less marked than they had been at
90 minutes. Discrimination between NAWM and grey
matter was very similar at 90 and 120 minutes. Amyloid
tracer clearance is slower from white matter than from
grey matter, which poses the question of what acquisi-
tion time is best and whether later acquisition times
might be suitable for white matter studies [24]. Our
findings do not seem to show later acquisition times to
be suitable for distinguishing between NAWM and
DWM or between white matter and grey matter. The
fact that MS patients show low amyloid tracer uptake in
grey matter probably indicates that discriminating be-
tween white matter and grey matter is unlikely to pose
problems. This finding may be useful in other circum-
stances (for example, studying such age-related disorders
as Alzheimer disease with associated white matter dis-
ease). However, further research into this specific subject
is needed [23].
Our study has several limitations. Firstly, it is a prelim-
inary study with a small sample size in which most of
the patients presented high lesion load. Furthermore, ac-
quired PET images were static and we were therefore
unable to conduct a tracer kinetic study to analyse tracer
behaviour in white matter over time. This approach
could provide a better understanding of the role of amyl-
oid PET in white matter diseases and possible modifica-
tions of the protocol of acquisition. However, the use of
a static protocol should not affect the main objectives
and results of the study regarding the reduction of PET
signal in white matter lesions. One of the difficulties en-
countered using static acquisition is that it does not pro-
vide a true quantification; in fact, measurements are
semi-quantitative and referenced to a region. Choosing
this region of reference may affect the results. We have
attempted to minimize this limitation by using two refer-
ence regions (cerebellum and white matter) and two
methods of analysis (semi-automatic and manual mea-
surements), in which the results have been reproduced.
Conclusions
Our study shows reduced 18F-florbetaben uptake in
white matter demyelinating lesions. These findings con-
firm that 18F-florbetaben is a marker of white matter dam-
age in MS and support earlier evidence suggesting that
amyloid tracers can be used to study white matter disease
[13, 15, 22, 23]. Our study suggests that 18F-florbetaben
may be useful in MS; however, longitudinal follow-up
studies and larger samples are needed to increase our un-
derstanding of the information provided by amyloid-PET
scans in patients with MS.
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